Objectives: Finafloxacin is an investigational fluoroquinolone exhibiting broad-spectrum activity that is enhanced under slightly acidic conditions (pH 5.0 -6.5). The impact of individual and combinations of chromosomal mutations (gyrA, parC and marR) and the plasmid-mediated fluoroquinolone resistance mechanisms QepA1, QnrA1, QnrB1, QnrS1 and AAC(6 ′ )-Ib-cr were investigated.
Introduction
The predominant mechanisms mediating clinically relevant resistance to fluoroquinolones in Escherichia coli are mutational alterations of the chromosomal target genes gyrA and gyrB as well as parC and parE, which encode subunits A and B of DNA gyrase and topoisomerase IV, respectively, and increased expression of multidrug resistance (MDR) efflux pumps, often due to inactivation of the repressor MarR. 1 Recently, three novel transferable plasmidmediated quinolone resistance (PMQR) mechanisms have been described. These include MDR efflux pumps QepA1 and QepA2, at least five different classes of topoisomerase protection proteins (QnrA, QnrB, QnrC, QnrD and QnrS) and the new variant AAC(6 ′ )-Ib-cr of the aminoglycoside acetyltransferase AAC(6 ′ )-Ib, capable of modifying C7-piperazinyl-fluoroquinolones. 2 Finafloxacin is a novel C-8-cyano-fluoroquinolone containing a unique chiral C7 substituent. Finafloxacin exhibits broadspectrum antibacterial activity that is enhanced over a pH range of 5.0 -6.5 compared with neutral and basic values. All other marketed fluoroquinolones, such as ciprofloxacin, levofloxacin and moxifloxacin, exhibit significantly reduced activity at slightly acidic pH (5.0-6.5). Therefore, finafloxacin is under development for hospital and critical care indications with acidic foci of infection. 3 The present study determined the impact of known chromosomal and PMQR mechanisms alone and in combination on the in vitro activity of finafloxacin at different pH values. For better comparability, the strains were all derived from E. coli isolate WT, 4 and the PMQR genes were (all) placed under the control of the plac promoter of plasmid vectors pUC18 or pUC19, except for qepA, which was cloned into pSTV28. 4 
Materials and methods

Antibiotics
Ampicillin sodium and kanamycin sulphate were purchased from Sigma-Aldrich (Munich, Germany). Fluoroquinolones were provided by the respective manufacturers: Bayer HealthCare, Leverkusen, Germany DNA isolation and manipulation, cloning of genes qnrA1, qnrB1, qnrS1 and aac(6 ′ )-Ib-cr and transformation
Plasmid isolation by the alkaline lysis method and transformation of CaCl 2 -treated competent cells with plasmid DNA followed standard protocols. 8 Except for qepA, genes mediating PMQR were individually amplified and cloned into vector pUC18 or pUC19 (Invitrogen, Germany), while cloning of gene aac(6 ′ )-Ib-cr required a two-step cloning procedure (see Supplementary data; available at JAC Online). The resulting recombinant plasmids, pUC19::qnrA1, pUC18::qnrB1, pUC19::qnrS1 and pUC19::aac(6 ′ )-Ib-cr, were characterized by DNA sequence analysis. Except for qnrA1, which carries its own promoter, this cloning strategy placed the remaining four genes under the control of the plac promoter, which is inducible by IPTG.
Susceptibility testing
MICs were determined at least in duplicate by broth microdilution in cation-adjusted Mueller-Hinton broth at pH values of 5.8 and 7.2.
Results
Impact of pH on fluoroquinolone activity
Results of the susceptibility testing are summarized in Table 1 . MICs of finafloxacin were lower by a factor of 2-8 at pH 5.8 compared with pH 7.2 for all strains tested. In contrast, the MICs of ciprofloxacin, levofloxacin and moxifloxacin were higher at pH 5.8 compared with pH 7.2 by factors of 8 -16, 8 and 4 -16, respectively.
At pH 5.8, finafloxacin MICs were 2-to 16-fold lower compared with the other fluoroquinolones tested, irrespective of the presence of chromosomally encoded or plasmid-encoded factors mediating fluoroquinolone resistance.
Impact of resistance mechanisms on fluoroquinolone activity
A comparison of the MICs of finafloxacin with those of ciprofloxacin, levofloxacin and moxifloxacin revealed a comparable increase by a factor of 8-16 for mutant MI, carrying a gyrA mutation, and a similar increase (factor of 4 -16) for the gyrA-parC double mutant WT-4-M-35. The acquisition of a marR deletion mutation in the absence (WT-III) or presence (MII) of an additional gyrA mutation resulted in an increase in the MICs of finafloxacin, ciprofloxacin and levofloxacin by a factor of 4, and a factor of 8 for moxifloxacin.
The MICs of finafloxacin were unaffected by the presence of the qepA gene at pH 5.8 and 7.2 (+ one serial dilution step), while the MICs of ciprofloxacin, levofloxacin and moxifloxacin were increased by factors of 8-64, 2 -4 and 2 -4, respectively.
In
For strains carrying a gyrA mutation (MI, MII and WT-4-M35), in the presence of the aac(6 ′ )-Ib-cr variant gene resulted in an increase of the MICs of ciprofloxacin determined at pH 5.8 and 7.2 by factors of 2-4 compared with the respective plasmid-free strain for each isogenic mutant. The MICs of the other three fluoroquinolones were unchanged (within one serial dilution step) for mutants carrying aac(6 ′ )-Ib-cr compared with the respective plasmid-free strains, except for moxifloxacin (factor of 4) with WT-III at pH 7.2. The MICs of kanamycin were increased by factors of 2 -4 and 32 for pH 5.8 and 7.2, respectively, compared with the parent strains, confirming gene expression from the aac(6 ′ )-Ib-cr promoter and indicating a pH-dependent acetylating activity of AAC(6 ′ )-Ib-cr on kanamycin.
Discussion
The impacts of pH and defined resistance mechanisms on the activity of finafloxacin compared with three other fluoroquinolones were evaluated by determining their MICs for a set of isogenic E. coli strains. Finafloxacin MICs were lower at pH 5.8 than at pH 7.2; conversely, the other fluoroquinolones were more active at pH 7.2 than at pH 5.8. Consequently, finafloxacin exhibited lower MICs than ciprofloxacin, levofloxacin and moxifloxacin at pH 5.8 for all strains tested. One notable finding is the drug-specific impact of QepA1: while finafloxacin retained its activity in the presence of QepA1, the activities of levofloxacin and moxifloxacin were slightly reduced and that of ciprofloxacin was significantly reduced (up to five serial dilution steps), the same reduction as reported by Yamane et al. 5 One explanation might be that the hydrophilic ciprofloxacin has higher affinity for QepA compared with the more hydrophobic fluoroquinolones levofloxacin and moxifloxacin, while lacking any affinity for finafloxacin. 9 Expression of Qnr topoisomerase protection proteins had the greatest impact on drug activity among the different fluoroquinolone resistance mechanisms. The increase in the MIC of finafloxacin by factors of 8 -32 and 4 -64 at pH 5.8 and 7.2, respectively, is comparable to that of ciprofloxacin (factors 4 -32 and 4 -64), but higher than those of moxifloxacin (factors of 4 -32 and 2 -16) and levofloxacin (factors of 2 -32 and 2-16). These data are comparable to those reported by Martínez-Martínez et al. 10 for E. coli J53 and E. coli J53 [pMG252] (QnrA1), as are the data reported by Jacoby et al. 11 for QnrB1 and by Hu et al. 12 for QnrS1. Moreover, in another study the pH-dependent finafloxacin activity 2531 JAC presence of plasmid pINF5 (qnrS1) alone resulted in an increase in MIC by a factor of 16. 7 An impact of aac(6 ′ )-Ib-cr gene expression on the reduction of fluoroquinolone activity under both pH conditions (5.8 and 7.2) was only evident with ciprofloxacin. This finding is in agreement with the data of Robicsek et al. 13 demonstrating the specificity of the variant AAC(6 ′ )-Ib-cr enzyme for a C7-piperazinyl substituent. In summary, under acidic conditions (pH 5.8), finafloxacin showed higher activity than ciprofloxacin, levofloxacin and moxifloxacin against strains expressing qepA, qnrA1, qnrB1, qnrS1 and aac(6 ′ )-Ib-cr, alone or in combination with chromosomal fluoroquinolone resistance mutations. The higher activity at acidic pH is a unique feature of finafloxacin and makes finafloxacin suitable for use in the treatment of infections in acidic environments, such as skin and skin structure infections, complicated urinary tract infections, intra-abdominal infections, infections of the lungs of cystic fibrosis patients and gastric infections by Helicobacter pylori. 
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